SmithKline halts trials in arthritis drug setback
Wednesday 25 June 1997
Analysts said news of the drug's suspension was a setback as it was one of the group's 10 blockbuster drugs due to be released before the year 2000, with potential peak sales of around pounds 300m. Shares in the group fell 19p to pounds 10.48.
Glaxo Wellcome, which is developing a similar class of drug - known as an anti-CD4 monoclonal antibody - for arthritis gained 6p to pounds 12.52.
Several drug companies are competing fiercely for a share of the multi- billion-dollar anti-arthritis market, where there is currently no effective treatment.
The phase-three trial results showed that 35 of the 103 patients completing the first month of treatment had reduced CD4 cell counts - indicating a weaker immune system - compared with just 10 of the larger phase-two trial.
Mark Brewer from Hoare Govett said: "This could be quite significant. SmithKline has been talking very positively about this drug. We expected it to make around pounds 20m in 2000 and pounds 300m in 2003. Anti-inflammatory and tissue repair is one of SmithKline's key research areas."
Kevin Scotcher from NatWest said that the potential side-effects from the drug were quite serious. "By making the immune system weaker, the drug creates an artificial HIV situation. This drug seems to work, but the side-effects may far outweigh the benefits."
However analysts said they were not changing their views on the stock. Mr Brewer said: "This is a good company with plenty in the pipeline if this one doesn't work."
James Culverwell, analyst at Merrill Lynch, said: "It's disappointing but pretty irrelevant for earnings. This was one of 10 potential blockbuster drugs due for release before 2000, including a follow-up close behind which might have a better profile."
A spokeswoman for SmithKline pointed out that no patients showed side- effects. She said the company was examining the possibility that the problems were due to simple manufacturing and increased dosages associated with scaling up the amount of product needed for larger-scale clinical trials.
"This drug is only on hold. We have not stopped development and we will be reviewing our manufacturing and dosing procedures."
- 1 Notting Hill Carnival: Woman shares selfie after being ‘punched in face for telling man to stop groping her’
- 2 Miley Cyrus' homeless MTV VMAs date, Jesse Helt, is wanted by the police
- 3 Pamela Anderson rejects ice bucket challenge because of ALS experiments on animals: 'Mice had holes drilled into their skulls'
- 4 Homer Simpson has taken the ALS ice bucket challenge because of course he has
- 5 Do you realise just how foolish the UK looks?
Notting Hill Carnival: Woman shares selfie after being ‘punched in face for telling man to stop groping her’
Gun instructor accidentally shot dead by nine-year-old girl with Uzi gun
Miley Cyrus' homeless MTV VMAs date, Jesse Helt, is wanted by the police
ALS ice bucket challenge co-founder Corey Griffin drowns, aged 27
The 13 obscure UK laws you didn’t know you were breaking
Exclusive: We share blame for creating 'jihad generation', says Muslim strategist
Robin Williams Emmys tribute led by Billy Crystal criticised for including 'racist' joke about Muslim woman
The Rotherham child abuse scandal is a tale of apologists, misogyny and double standards
Scottish independence TV debate: Pumped-up Alex Salmond bounces back in bruising second round against Alistair Darling
Jeremy Clarkson is a cultural tumour and needs to be removed, says comedian Frankie Boyle
Air strikes? Talk of God? Barack Obama is following the jihadists’ script after James Foley beheading
- < Previous
- Next >
iJobs Money & Business
£500 - £700 per day: Harrington Starr: Calypso Developer Calypso, J2SE, XML, ...
£35000 - £36000 per annum + benefits: Ashdown Group: A market leading financia...
£250 - £350 per annum + competitive: Orgtel: My client, a leading bank, is cur...
£23000 - £26000 per annum: Ashdown Group: Account Executive / Client Services ...